Experimental Vaccine Triggers Immune Response in Pancreatic Cancer Patients
An experimental pancreatic cancer vaccine called camupepimut triggered a measurable immune response in 98.9% of treated patients during a phase 2 clinical trial, according to findings published in Nature Medicine and covered by Slow News. Pancreatic ductal adenocarcinoma remains one of the most aggressive and treatment-resistant malignancies, with driver mutations in the KRAS gene occurring in roughly 90% to 95% of cases. Developed by Elicio Therapeutics, camupepimut targets seven common KRAS mutations to train patient T-cells against tumor cells. Unlike personalized vaccines, camupepimut is not manufactured individually for each patient, as the treatment is designed for individuals presenting with matching mutations.
Phase 2 Clinical Trial Design and Patient Demographics
The AMPLIFY-7P trial enrolled 144 patients who had previously undergone surgery and chemotherapy without any visible signs of remaining tumor Newspaper. Pathomorphological analysis of the resected tissue showed that 31.3% of participants had stage I disease, 42.7% had stage II, and 26.0% had stage III PCR.news. Researchers randomized 96 participants to receive the vaccine while 48 individuals served as a control observation group. Patients in the treatment arm received a median of six primary doses and four booster doses. The clinical evaluation recorded a median follow-up duration of 19.4 months. Among enrolled individuals, the required inclusion criteria specified the presence of a targeted KRAS mutation, specifically G12D, G12R, G12V, G12A, G12C, G12S, or G13D. Throughout the course of treatment, none of the participants required discontinuation of therapy, though temporary dose adjustments due to adverse events became necessary for five patients, accounting for 5.2% of the treatment group.
Immune System Activation and T-Cell Activity
Out of 90 vaccine recipients evaluated for immune response, 89 showed an increase in T-lymphocyte activity against mutated KRAS Slow News. More than 80% of participants experienced a greater than ninefold increase in this specific cellular response compared to baseline Newspaper. The trial data indicated that higher T-cell activation correlated with longer periods without disease progression PCR.news. The therapy demonstrated a manageable safety profile, with grade 3 or higher adverse events occurring in 10.4% of the vaccine group versus 14.6% in the control group PCR.news.
Survival Rates and Statistical Significance
Despite the strong immunological reaction, the trial missed its primary endpoint for overall disease-free survival across the entire cohort Newspaper. The median disease-free survival reached 23.8 months for the vaccine group compared to 21.2 months in the control group, a difference that investigators found to be statistically insignificant PCR.news. However, secondary analyses noted that six months after treatment began, 75.7% of the vaccine group showed no signs of disease compared to 61.7% in the observation arm PCR.news. Within the treatment group, 75%, representing 72 people, completed the treatment course, whereas 30 participants in the observation group, equaling 62.5%, remained in the study until completion.
Future Trial Phases and Next Research Steps
The research team plans to utilize the immunological and efficacy data gathered from the phase 2 study to design a phase 3 clinical trial PCR.news. Investigators are looking to refine patient selection strategies and evaluate potential signals of benefit observed in subgroups lacking detectable tumor DNA in their blood or those who avoided prior radiation therapy Newspaper.
Keep reading